India, Aug. 12 -- PolyPid Ltd. (PYPD), an innovative biopharmaceutical company developing long-acting, controlled-release therapies, reported second-quarter 2026 financial results and corporate updates, highlighting FDA acceptance of D-PLEX100's NDA with Priority Review and a commercialization partnership with Azurity Pharmaceuticals.
Company Profile
PolyPid focuses on developing localized, controlled-release therapies designed to improve treatment effectiveness at the site of care. Its lead program, D-PLEX100, is being developed to prevent surgical site infections following abdominal colorectal surgery.
Pipeline Update
D-PLEX100 for Surgical Site Infections
On June 1, 2026, PolyPid completed its NDA submission for D-PLEX100, supported...